Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/dinto_DB08901
http://purl.obolibrary.org/obo/dinto_DB08901
|
|---|---|
| Preferred Name | ponatinib |
| Synonyms |
3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide
C29H27F3N6O
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | ponatinib
|
|---|---|
| label | ponatinib
|
| DBSynonym | ap24534
|
| ATCCode | L01XE24
|
| Definition | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
|
| DBSalt | ponatinib hydrochloride
|
| has pharmacological target | |
| inhibits |
See more
See less
|
| type | |
| InChIKey | InChIKey=PHXJVRSECIGDHY-UHFFFAOYNA-N
|
| is metabolised by | |
| AHFScode | 10:00
|
| Synonym | 3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide
C29H27F3N6O
|
| xref |
Drugs.com:http://www.drugs.com/mtm/ponatinib.html
Wikipedia:http://en.wikipedia.org/wiki/Ponatinib
National Drug Code Directory:76189-534-30
|
| CASRN | 943319-70-8
|
| prefixIRI | obo2:dinto_DB08901
|
| is transported by | |
| SMILES | CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1
|
| may interact with |
See more
See less
|
| InChI | InChI=1/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
|
| DBBrand | iclusig
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |